IFNA1 and neoplasm: IFNα and IFNβ released by engineered CAR T-cells, in addition, can potentially sustain the anti-tumor attack of CAR T-cells, in particular by blocking proliferation and induction of apoptosis in malignant cells, destruction of tumor-associated blood vessels, increase of MHC expression on malignant cells, promotion of dendritic cell and macrophage functionality, and activation of NK cells [34].